REG - Aptamer Group PLC - Aptamer Group signs two substantial new contracts

AptamerAnnouncement

24/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230124:nRSX6087Na&default-theme=true

RNS Number : 6087N  Aptamer Group PLC  24 January 2023

24 January 2023

 

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

 

Aptamer Group signs two substantial new contracts

 

-     Contracts worth over £500,000 with the potential for downstream
milestone and royalty/ licensing payments

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders
to enable innovation in the life sciences industry, announces the recent
signing of two new fee-for-service contracts initially worth over £500,000,
subject to the successful progression of Optimer development, with the
potential for downstream milestone and royalty/licensing payments. These
latest contracts are in addition to £1.0m of recognised revenue in H1, as
well as the additional £1.0m in signed orders, announced in Aptamer's recent
trading update.

 

The first contract is with BaseCure Therapeutics, a pre-clinical stage biotech
company dedicated to the discovery and development of innovative siRNA-based
medicines. Aptamer is working with BaseCure Therapeutics to identify cell
targeting Optimer binders that might be developed as potential delivery
vehicles for siRNA uptake into target cells and tissues. The ability to
achieve Optimer-directed targeted delivery would offer exciting new
therapeutic opportunities of siRNA-mediated gene knockdown in these target
cells and tissues.

 

The second contract is with a developer of custom enzymes based in Asia.
Aptamer will develop Optimer binders for incorporation into a biosensor to
allow convenient monitoring of the ingredients in the company's manufacturing
processes. As these ingredients are typically small molecule targets,
antibodies often struggle to develop the required levels of selectivity to
these targets.

 

Dr Arron Tolley, Chief Executive Officer, commented: "Signing these two
substantial deals is a solid start to the second half for Aptamer Group. The
diverse nature of these partnerships demonstrates the broad applicability of
the Optimer platform across the life science industry, from supporting
improved manufacturing methods to developing new drugs and the increased need
for novel antibody alternatives within the life science market. I look forward
to updating the market regarding progress for these deals and new partnerships
in due course."

 

- ENDS -

 

For further information, please contact:

 

Aptamer Group plc

Dr Arron Tolley
 
     +44 (0) 1904 217 404

SPARK Advisory Partners Limited - Nominated Adviser

Andrew Emmott / Adam
Dawes
+44 (0) 20 3368 3550

Liberum Capital Limited - Broker

Richard Lindley / Ben Cryer / Cara Murphy
 
+44 (0) 20 3100 2000

Consilium Strategic Communications

Matthew Neal / Chris Welsh / Lucy Featherstone
                +44 (0) 20 3709 5700

aptamergroup@consilium-comms.com (mailto:aptamergroup@consilium-comms.com)

 

About Aptamer Group plc

Aptamer (http://www.aptamergroup.com/) Group develops custom affinity binders
through its proprietary Optimer(®) platform to enable new approaches in
therapeutics, diagnostics and research applications. The Company strives to
deliver transformational solutions that meet the needs of life science
researchers and developers through the use of its proprietary Optimer
platform.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global antibody market is currently worth over
$145.0 billion. Optimer binders are engineered to address many of the issues
found with alternative affinity molecules, such as antibodies, and offer new,
innovative solutions to bioprocessing, diagnostic and pharmaceutical
scientists.

Aptamer Group has successfully delivered projects for global pharma companies,
diagnostic development companies, and research institutes covering a range of
targets and applications with the objective of establishing royalty-bearing
licenses. Through the unique Optimer technology and processes, scientists and
collaborators are enabled to make faster, more informed decisions that support
discovery and development across the Life Sciences.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBIGDBBXDDGXX